The CREDO Research Project: Can mood problems be prevented and treated using e-health interventions in patients being treated for cardiovascular disease?

Not Applicable

Completed

• Conditions: Depression; Cardiovascular Disease; Cognitive function; Mental Health - Depression; Cardiovascular - Coronary heart disease; Mental Health - Studies of normal psychology, cognitive function and behaviour

• Registration Number: ACTRN12610000085077
• Lead Sponsor: The University of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-01-25
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

1. Participant in the logitudinal cohort, the 45 and Up Study
2. Aged 45 to 75 years at date of sampling
3. Self-reported history of cardiovascular disease as collected within the 45 and Up Study baseline data
4. Positive screen for depressive symptoms as collected within the baseline 45 and Up Study data
5. Provided informed consent to participate and link their data with that of Medicare Australia and NSW Health Services.

Exclusion Criteria

Exclusion criteria will be applied at the time of screening entry to the trial as follows: 1. No depressive symptoms, as determined using the PHQ-9 (scores less than or equal to 7 on the 27-point scale). 2. Suicidal ideation determined from the PHQ-9. 3. Current psychotherapy of any form.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
A change in severity of depressive symptoms, as measured using the Patient Health Questionnaire (PHQ-9). This 9-item assessment tool, designed for community samples, provides a summary score ranging from 0 to 27. Participants meeting the cut point on the PHQ-9 depression score suggestive of more than moderate (greater than 9) results will be considered positive as having depressive symptoms.[Changes will be measured from baseline to 3 months (post-intervention).]

Secondary Outcome Measures

Name	Time	Method
Changes in cognitive function, as measured using internet deliverable computerised cognitive tasks (CogState) with well established validity and sensitivity to slowing of psychomotor function and impairment of attention, working memory and new learning abilities.[Changes in cognitive function will be measured from baseline to 3 months (post-intervention), 6 months and 12 months.];Changes in adherence to treatment for cardiovascular disease, using the Medical Outcomes Study Measures of Patient Adherence Scale.[Changes in adherence to treatment for cardiovascular disease will be measured from baseline to 3 months (post-intervention), 6 months and 12 months.]